Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Frank-Ito (Durham, NC, United States of America). Orally inhaled drug particle deposition efficiency in subjects with two-level laryngotracheal stenosis. 3187

Member's Comments

No comment yet.

Related content which might interest you: Placing a mask on COVID-19 patients during high-flow nasal cannula therapy reduces aerosol particle dispersion Source: ERJ Open Res, 7 (1) 00519-2020; 10.1183/23120541.00519-2020 Year: 2021 Extent of inhaled drug deposition at variable inhaler inclination angles and airway geometries: An in-vivo study from a novel computational fluid dynamics model Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Efficient deposition and absorption of orally inhaled indacaterol in the lungs Source: Annual Congress 2011 - COPD management Year: 2011 Inhaled long-acting β2-agonist: aerosol particle size and bronchodilator response Source: Eur Respir J 2005; 26: Suppl. 49, 126s Year: 2005 In vitro analysis of two formulations of fluticasone/ salmeterol pMDI for delivered dose uniformity and aerodynamic particle size distribution Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation Source: Eur Respir J 2011; 38: 1328-1335 Year: 2011 Inhaled corticosteroid fine particle dose from valved holding chambers Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010 Effect of paclitaxel delivered nanoparticles to treat tracheal stenosis Source: International Congress 2015 – Advances in therapeutic bronchoscopy Year: 2015 Slow particle dissolution may limit lung absorption of inhaled pharmaceuticals in the lungs Source: Eur Respir J 2006; 28: Suppl. 50, 210s Year: 2006 Surgical facemask affects fugitive emissions during aerosol drug delivery by high-flow nasal therapy Source: Virtual Congress 2021 – COVID-19 and acute respiratory failure Year: 2021 Precise dosing of five drugs commonly used by patients with cystic fibrosis using an adaptive aerosol delivery system Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools Year: 2008 Improvement of small airway deposition of corticosteroids by smart nebulisation Source: International Congress 2018 – Asthma and drugs Year: 2018 A submicron suspension of budesonide improves the mass of ICS delivered during early nebulization Source: Eur Respir J 2006; 28: Suppl. 50, 712s Year: 2006 Numerical simulation of the effect of inhalation parameters and disease severity on the deposition of dry powder aerosol drugs in COPD patients Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more Year: 2020 Small airway function in asthma patients treated with an ultrafine inhaled steroid aerosol Source: Eur Respir J 2004; 24: Suppl. 48, 581s Year: 2004 Successful conversion of patients using nebulised iloprost from multisonic nebuliser to adaptive aerosol delivery nebuliser Source: Eur Respir J 2007; 30: Suppl. 51, 345s Year: 2007 Effect of the actuator orifice diameter on the biodisposition of a new budesonide CFC-free metered dose inhaler formulation Source: Eur Respir J 2001; 18: Suppl. 33, 102s Year: 2001 Extent of inhaled drug deposition in mouth-throat and pulmonary airways: A novel biophysical modelling approach for inhaled therapeutics Source: International Congress 2015 – New models for treating airway diseases Year: 2015 In vitro fine particle dose of drug formulation used in asthma & COPD Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies Year: 2020 Comparison of systemic bioavailability of two formulations of budesonide nebulized suspension in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009